Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

World Health Matters: Italy: Leukaemia death rate expected to fall in 2016

Written by | 22 Feb 2016

by Gary Finnegan: Good news in the battle against cancer: death rates from leukaemia among people of all ages in Europe are falling.

EMA Highlights: EMA gives green light for new drugs

Written by | 23 Dec 2015

by Gary Finnegan: Ten medicines, including a first-in-class orphan medicine for narcolepsy, were recommended for authorisation in the EU at the latest meeting of the European Medicines Agency’s Committee for Medicinal… read more.

Resection safe and helpful for high-risk, early-stage lung cancer patients

Written by | 11 Dec 2015

by Bruce Sylvester: Surgical resection is a safe and helpful treatment option for a broad range of patients with early-stage lung cancer, researchers reported online on  Nov. 10,… read more.

EMA Highlights: Green light for new medicines

Written by | 13 Oct 2015

by Gary Finnegan: The European Medicines Agency’s key committee approved a total of 19 new medicines at its meeting in late September – the highest number of products… read more.

Can asthma protect men from lethal prostate cancer?

Written by | 9 Oct 2015

Men with asthma are less likely to have aggressive prostate cancer or to die from the disease, according to a large, prospective cohort study published in the International… read more.

Effective use of Firmagon (degarelix) for advanced prostate cancer

Written by | 2 Oct 2015

Firmagon (Degarelix) is a competitive, reversible GnRH receptor blocker, for patients with advanced hormone-dependent prostate cancer.  Where Injection technique is critical;  Nora Sullivan, a specialist nurse at Hibernian… read more.

Green light for new medicines

Written by | 31 Aug 2015

by Gary Finnegan: The European Medicines Agency’s influential Committee for Medicinal Products for Human Use (CHMP) has given the green light for ten new medicines, as well as offering… read more.

Rociletinib could become a “game changer” in treating EGFR-mutation driven lung tumors which have become treatment resistant

Written by | 6 Jul 2015

by Bruce Sylvester: Rociletinib, an investigative therapy for treatment resistant EGFR-mutation driven lung tumors, shows activity against the most common resistance mutation, and it significantly improves clinical  outcomes.

ASCO 2015 Report: Pembrolizumab shows “remarkable” efficacy in head and neck cancer

Written by | 8 Jun 2015

by Bruce Sylvester: Pembrolizumab (Keytruda®), an anti-PD-1 antibody immunotherapy has shown efficacy in one fourth of patients with recurrent or metastatic head and neck cancer, researchers reported on… read more.

ASCO Report 2015: Immunotherapy nivolumab improves survival in squamous-non-small cell lung cancer

Written by | 4 Jun 2015

by Bruce Sylvester: In a Phase III trial comparing standard docetaxel chemotherapy with immunotherapy nivolumab, researchers reported that subjects with squamous-non-small cell lung cancer treated with nivolumab lived… read more.

Psychologists aim to help Dr. Google

Written by | 13 May 2015

Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek… read more.

Melanoma drugs show efficacy in BRAF-mutant lung cancer

Written by | 5 May 2015

by Bruce Sylvester: Lung cancer patients whose tumors carry specific mutations in the BRAF gene appear to benefit from drugs used to treat melanoma, researchers from the retrospective… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.